Ocular manifestations and treatment progress of Parry-Romberg syndrome.

IF 1.4 4区医学 Q3 OPHTHALMOLOGY

International Ophthalmology Pub Date : 2025-05-17 DOI:10.1007/s10792-025-03574-7

Dengfeng Zhang, Shuting Huang, Xin Zhang, Le Ling, Bei Li

{"title":"Ocular manifestations and treatment progress of Parry-Romberg syndrome.","authors":"Dengfeng Zhang, Shuting Huang, Xin Zhang, Le Ling, Bei Li","doi":"10.1007/s10792-025-03574-7","DOIUrl":null,"url":null,"abstract":"Purposes: Parry-Romberg syndrome is a rare degenerative disease. This article focuses on the ocular aspects of Parry-Romberg syndrome to help diagnose and further explore more effective treatments.Methods: A combined systematic search of PubMed electronic database by using Boolean operators AND and OR was conducted, choosing the following keywords: \"Parry-Romberg syndrome\", \"Progressive hemifacial atrophy\", \"eye\", \"oculus\", \"ophthalmic\", \"ophthalmologic\", \"ophthalmology\" and \"global\", etc. After the initial screening of these articles, repetitive literatures were excluded.Results: 69 articles were selected. This study introduces the ocular manifestations, possible pathogenesis, and treatment progress of Parry-Romberg syndrome.Conclusion: There is currently no clear pathogenesis and effective treatment for Parry-Romberg syndrome. Understanding its pathological mechanism in the context of autoimmune etiology and exploring its phenotype-genotype correlation may help find more valuable treatments.","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"45 1","pages":"202"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-025-03574-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purposes: Parry-Romberg syndrome is a rare degenerative disease. This article focuses on the ocular aspects of Parry-Romberg syndrome to help diagnose and further explore more effective treatments.

Methods: A combined systematic search of PubMed electronic database by using Boolean operators AND and OR was conducted, choosing the following keywords: "Parry-Romberg syndrome", "Progressive hemifacial atrophy", "eye", "oculus", "ophthalmic", "ophthalmologic", "ophthalmology" and "global", etc. After the initial screening of these articles, repetitive literatures were excluded.

Results: 69 articles were selected. This study introduces the ocular manifestations, possible pathogenesis, and treatment progress of Parry-Romberg syndrome.

Conclusion: There is currently no clear pathogenesis and effective treatment for Parry-Romberg syndrome. Understanding its pathological mechanism in the context of autoimmune etiology and exploring its phenotype-genotype correlation may help find more valuable treatments.

查看原文本刊更多论文

Parry-Romberg综合征的眼部表现及治疗进展。

目的：Parry-Romberg综合征是一种罕见的退行性疾病。本文主要关注Parry-Romberg综合征的眼部方面，以帮助诊断和进一步探索更有效的治疗方法。方法：采用布尔运算符AND和OR对PubMed电子数据库进行联合系统检索，选择关键词：“Parry-Romberg综合征”、“进行性面瘫”、“eye”、“oculus”、“ophthalmic”、“ophthalmologic”、“ophthalmology”、“global”等。在对这些文章进行初步筛选后，排除重复的文献。结果：共入选69篇。本文介绍了Parry-Romberg综合征的眼部表现、可能的发病机制及治疗进展。结论：Parry-Romberg综合征的发病机制和有效治疗方法尚不明确。在自身免疫病因背景下了解其病理机制并探索其表型-基因型相关性可能有助于发现更有价值的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

451

期刊介绍： International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.